Catalyst
Slingshot members are tracking this event:
Rubraca (rucaparib) Approved in the U.S. as Maintenance Treatment of Recurrent Ovarian Cancer
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| CLVS |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 06, 2018
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Rucaparib, Rubraca, Recurrent Ovarian Cancer
